How to improve the cure rate of early kidney cancer

Kidney cancer is the most common kidney tumor in adults, and the incidence rate is increasing year by year. When the size is larger than 3cm, it is very easy to metastasize. Due to the hidden location of the kidney, kidney cancer usually has no obvious symptoms in the early stage, and most patients are in the middle and late stages when they are discovered. The following is a detailed introduction on how to improve the cure rate of early kidney cancer?

Since kidney cancer is not very sensitive to radiotherapy, and chemotherapy is also ineffective in treating kidney cancer, the clinical treatment of early kidney cancer mainly relies on radical resection surgery. Although some anti-recurrence treatments are performed after surgery, there are still big problems.
Difficulties in treating early renal cancer:
1. Kidney cancer is very special. It is insensitive to traditional chemotherapy or hormone therapy, and it is difficult to prevent recurrence after surgery.
2. As a postoperative auxiliary treatment, traditional Chinese medicine can only help patients recover their physical condition and improve their quality of life to a certain extent, but it cannot directly kill cancer cells in the patient's body. It cannot achieve the purpose of reducing postoperative recurrence rate and improving long-term survival rate.
Characteristic treatment plan for early renal cancer: surgery + biological cell immunotherapy. On the basis of maintaining radical surgical treatment, our center has introduced CIK cell immunotherapy, which is currently recognized as the most advanced biological immunotherapy technology in the world, in terms of postoperative recurrence prevention. That is, CIK cell immunotherapy is immediately applied to patients with early renal cancer after resection surgery to prevent tumor recurrence and metastasis. It has a definite effect on killing residual lesions and cancer cells of renal cancer, significantly reducing the postoperative recurrence rate, and raising the treatment effect of early renal cancer to a new level. It has made essential progress.